Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$21.82
-$0.05(-0.51%)
At close: 4:00 PM EST
$21.82
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$8.91 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)602.22K
Market Cap
$1.25B
Enterprise Value$680.97M
Total Cash (Recent Filing)$717.21M
Total Debt (Recent Filing)$351.73M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 18, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.10
Shares Outstanding63,133,377
10 Day Avg. Volume733,019
30 Day Avg. Volume602,215
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.18
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$41.40Price Target Upside89.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.81
Revenue Forecast (FY)$21.88M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 Data For ObexelimabRobust INDIGO Phase 3 results (56% flare-risk reduction) materially de-risk the lead asset, supporting regulatory submissions and a potential first-in-class launch. This outcome strengthens long-term commercial prospects and justifies continued late-stage investment and partner interest.
Substantial Financing Extends Cash RunwayLarge recent financings and cash balance extend runway into 2029, providing the company durable funding to complete key registrational programs and prepare for commercialization. This materially reduces near-term funding risk and enables sustained R&D investment while trials read out.
Diversified Late- And Early-stage PipelineMultiple late- and early-stage programs broaden the company’s opportunity set beyond a single asset, providing strategic optionality. A pipeline spanning autoimmunity and neuro indications increases chances of future approvals and revenue streams, lowering binary outcome risk.
Bears Say
High Operating Cash BurnSustained negative operating cash flow (~$210M TTM) means the business consumes large cash to fund operations and trials. Unless revenue or margins improve, the company will remain dependent on external financing, creating recurring dilution and execution pressure over the medium term.
Very Small, Volatile Revenue BaseA $10M revenue base and pronounced volatility (‑50% YoY) provide little internal funding and signal limited commercial traction today. This forces reliance on capital markets for growth and increases the operational risk if regulatory or launch timelines slip.
Rapidly Rising Debt And LeverageDebt has increased materially in a short period, raising leverage and fixed obligations. Higher debt amplifies refinancing and covenant risk if losses persist, constrains financial flexibility, and increases the potential cost of capital for future strategic moves.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $8.91 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.25B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 58 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on May 13, 2026. The company reported -$1.46 earnings per share for the quarter, beating the consensus estimate of -$1.474 by $0.014.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.12.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 63,133,377 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.46 in its last earnings report, beating expectations of -$1.474. Following the earnings report the stock price went up 4.019%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.40 (89.73% Upside)
$41.40 (89.73% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 740.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
112.45%
12-Months-Change
Fundamentals
Return on Equity
-167.71%
Trailing 12-Months
Asset Growth
124.01%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$41.40
▲(89.73% Upside)
Technical Analysis
Ownership Overview
25.17% Insiders
20.27% Mutual Funds
47.33% Other Institutional Investors
0.37% Public Companies and Individual Investors